0001209191-23-024116.txt : 20230412 0001209191-23-024116.hdr.sgml : 20230412 20230412170359 ACCESSION NUMBER: 0001209191-23-024116 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230410 FILED AS OF DATE: 20230412 DATE AS OF CHANGE: 20230412 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ross Thomas M. CENTRAL INDEX KEY: 0001874572 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40674 FILM NUMBER: 23816315 MAIL ADDRESS: STREET 1: C/O MAXCYTE, INC. STREET 2: 22 FIRSTFIELD ROAD, SUITE 110 CITY: GAITHERSBURG STATE: MD ZIP: 20878 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MAXCYTE, INC. CENTRAL INDEX KEY: 0001287098 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 522210438 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 301-517-5556 MAIL ADDRESS: STREET 1: 22 FIRSTFIELD ROAD STREET 2: SUITE 250 CITY: GAITHERSBURG STATE: MD ZIP: 20878 FORMER COMPANY: FORMER CONFORMED NAME: MAXCYTE INC DATE OF NAME CHANGE: 20040415 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-10 0 0001287098 MAXCYTE, INC. MXCT 0001874572 Ross Thomas M. C/O MAXCYTE, INC. 9713 KEY WEST AVENUE, SUITE 400 ROCKVILLE MD 20850 0 1 0 0 EVP, Global Sales & Marketing 1 Common Stock 2023-04-10 4 M 0 100 2.142 A 100 D Common Stock 2023-04-10 4 S 0 100 5.00 D 0 D Common Stock 2023-04-11 4 M 0 8451 2.142 A 8451 D Common Stock 2023-04-11 4 S 0 8451 5.00 D 0 D Common Stock 2023-04-12 4 M 0 5583 2.142 A 5583 D Common Stock 2023-04-12 4 S 0 5583 5.00 D 0 D Employee Stock Option (right to buy) 2.142 2023-04-10 4 M 0 100 0.00 D 2029-03-04 Common Stock 100 27902 D Employee Stock Option (right to buy) 2.142 2023-04-11 4 M 0 8451 0.00 D 2029-03-04 Common Stock 8451 19451 D Employee Stock Option (right to buy) 2.142 2023-04-12 4 M 0 5583 0.00 D 2029-03-04 Common Stock 5583 13868 D The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 6, 2022. The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. This option is fully vested and exercisable. /s/ Brian F. Leaf, Attorney-in-Fact 2023-04-12